Efficacy and safety of transurethral alprostadil therapy in men with erectile dysfunction

British Journal of Urology

Volumn 81, Issue 6, 1998, Pages 889-894

  Williams, G ^a   Abbou, C C ^b   Amar, E T ^c   Desvaux, P ^d   Flam, T A ^e   Lycklama Nijeholt, G A B ^f   Lynch, S F ^g   Morgan, R J ^h   Muller S C ⁱ   Porst, H ^j   Pryor, J P ^k   Ryan, P ^l   Witzsch, U K F ^m   Hall, M M ^a   Place, V A ^a   Spivack, A P ^a   Gesundheit, N ^b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b HENRI MONDOR HOSPITAL   (France)

^c Chirurgie Ilrologique et Andrologique   (France)

^d HÔPITAL TENON   (France)

^e Hôpital Cochin ^*  (France)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^g The Surgery   (Ireland)

^h ROYAL FREE HOSPITAL   (United Kingdom)

ⁱ UNIVERSITY OF BONN   (Germany)

^j Middlesex Hospital ^*

^k Department of Pharmacology and Therapeutics   (United Kingdom)

^l DR HORST SCHMIDT KLINIKEN   (Germany)

^m Menlo Park and VIVUS   (Germany)

more..

Author keywords

Alprostadil; Erectile dysfunction; Transurethral application

Indexed keywords

PLACEBO; PROSTAGLANDIN E1;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EUROPE; HUMAN; HYPOTENSION; INTRAURETHRAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MALE SEXUAL DYSFUNCTION; MULTICENTER STUDY; OUTPATIENT; PAIN; PENIS ERECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UROGENITAL SYSTEM; VERTIGO;

ADULT; AGED; ALPROSTADIL; AMBULATORY CARE; COITUS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION ROUTES; HUMANS; IMPOTENCE; MALE; MIDDLE AGED; SELF ADMINISTRATION; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 7144251198     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.1998.00703.x     Document Type: Article

References (14)

1. Padma-Nathan H, Hellstrom WJG, Kaiser FE et al Treatment of men with erectile dysfunction with transurethral alprostadil. N Engl J Med 1997: 336: 1-7
2. Hellstrom WJG, Bennett AH. Gesundheit N et al. Multicenter, double-blind, placebo-controlled evaluation of the erectile response to transurethral alprostadil in men with chronic erectile dysfunction. Urology 1996; 48: 851-6
3. Waldhauser M, Schramek P. Efficiency and side effects of prostaglandin El in the treatment of erectile dysfunction. J Urol 1988; 140: 525-7
4. Ishii N, Watanabe H, Irisawa C et al. Intracavernous injection of prostaglandin El for the treatment of erectile impotence. J Urol 1989; 141: 323-5
5. Muller SC. [Pathophysiology of erectile dysfunction diagnostic and therapeutic consequences]. Aktuelle Radial 1991; 1: 28-33
6. Miller MA. Morgan RJ. Eicosanoids. erections and erectile dysfunction. Prostaglandins Leukotrienes Essential Fatty Acids 1994: 51: 1-9
7. Kirby RS. Impotence: diagnosis and management of male erectile dysfunction. Br Med J 1994; 308: 957-61
8. Amar E. Kobelinsky M, Khoury R et al. Treatment of sexual impotency by intra-cavernous injections of prostaglandin El. Report of 180 patients. Prog Urol 1993: 3: 971-8
9. Linet 01, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. N Engl J Med 1996; 334: 873-7
10. Ryan PG, Wallace DM. Therapeutic progress - Review XXXVI. Are we making progress in the drug treatment of disorders of the bladder, prostate, and penis? J Clin Pharm Ther 1990; 15: 1-12
11. Porst H. The rationale for prostaglandin El in erectile failure: a survey of worldwide experience. J Urol 1996; 155: 802-15
12. Padma-Nathan H, Goldstein I, Payton T, Krane RJ. Intracavernosal pharmacotherapy: the pharmacologie erection program. World] Urol 1987; 5: 160-5
13. Althof SE. Turner LA, Levine SB et al. Why do so many people drop out from auto-injection therapy for impotence? J Sex Marital Ther 1989; 15: 121-9
14. Vardi Y, Saenz de Tejada I. Functional and radiologie evidence of vascular communication between the spongiosal and cavernosal compartments of the penis. Urology 1997; 49: 749-52